Health · 1 sources covering this

STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more

An FDA panel recommended that compounding pharmacies be allowed to make two more peptides, a step toward RFK Jr.'s goal to make them more available

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
An FDA panel recommended that compounding pharmacies be allowed to make two more peptides, a step toward RFK Jr.'s goal to make them more available
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/3538a782e9048b712c53164dbe6c7297c44e265f"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about a U.S. peptide panel&#8217;s votes, Amgen scuffling with the FDA, and more"></iframe>

STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more

How 1 sources are covering this

STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more

More from Health

STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

A trend that isn’t fading, ultra-processed baby foods

STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Pharmalittle: We&#8217;re reading about a U.S. peptide panel&#8217;s votes, Amgen scuffling with the FDA, and more

More from Health

STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor&#8217;s Duchenne drug

A trend that isn&#8217;t fading, ultra-processed baby foods

STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

A trend that isn’t fading, ultra-processed baby foods